| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Samuel J Klempner | Q57371904 |
| P2093 | author name string | Phu Tran | |
| Cham Nguyen | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway | Q26825780 | ||
| Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum | Q27851722 | ||
| The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere | Q27852562 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Characterization of PDK2 activity against protein kinase B gamma | Q28216896 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis | Q28246808 | ||
| Upstream and downstream of mTOR | Q28277365 | ||
| Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay | Q28611936 | ||
| The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Cancer incidence trends among Asian American populations in the United States, 1990-2008 | Q30542355 | ||
| Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers | Q33422778 | ||
| Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals | Q33760578 | ||
| The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. | Q33833156 | ||
| A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma | Q34458117 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction | Q34603020 | ||
| Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial | Q34627996 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. | Q35412202 | ||
| Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. | Q54513779 | ||
| The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. | Q54535188 | ||
| The prevalence of PIK3CA mutations in gastric and colon cancer. | Q54655912 | ||
| Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. | Q54671174 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Variation in incidence of and mortality from stomach cancer, with particular reference to the United States | Q78334145 | ||
| Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. | Q35430015 | ||
| Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies | Q35586700 | ||
| Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression | Q35606679 | ||
| PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors | Q35838565 | ||
| Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). | Q36108820 | ||
| Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition | Q36320600 | ||
| Chemotherapy for gastric cancer. | Q36398226 | ||
| Targeting von Hippel-Lindau pathway in renal cell carcinoma | Q36692585 | ||
| The life of a cell: apoptosis regulation by the PI3K/PKB pathway | Q37289433 | ||
| Combined modality therapy of esophageal cancer | Q37300119 | ||
| An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma | Q37300142 | ||
| PTEN in cancer, metabolism, and aging. | Q37331397 | ||
| Status of PI3K inhibition and biomarker development in cancer therapeutics | Q37588308 | ||
| Targeting mTOR globally in cancer: thinking beyond rapamycin | Q37630203 | ||
| Advanced gastric cancer--slow but steady progress | Q37696790 | ||
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer | Q37709811 | ||
| PTEN level in tumor suppression: how much is too little? | Q37832338 | ||
| PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types | Q38084846 | ||
| HER2 expression and PI3K-Akt pathway alterations in gastric cancer. | Q38181377 | ||
| Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil | Q38490073 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors | Q39099207 | ||
| β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer | Q39345531 | ||
| RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase | Q39665088 | ||
| Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial | Q39668099 | ||
| mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo | Q39703807 | ||
| Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo | Q39949820 | ||
| Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha | Q39952263 | ||
| Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model | Q40182123 | ||
| A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | Q41699326 | ||
| PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis | Q42011584 | ||
| Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation | Q44808305 | ||
| Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice | Q45408476 | ||
| Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States | Q46325747 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | Suppl 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S131-140 | |
| P577 | publication date | 2016-11-22 | |
| P1433 | published in | International neurourology journal | Q26842093 |
| P1476 | title | Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? | |
| P478 | volume | 20 |
| Q41545361 | AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells |
| Q37517843 | Are We Ready to Use the Omics Strategies for Precision Medicine? |
| Q52586720 | Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway. |
| Q89341658 | DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer |
| Q38699551 | Deoxyelephantopin and Isodeoxyelephantopin as Potential Anticancer Agents with Effects on Multiple Signaling Pathways. |
| Q58593875 | PI3K-Akt-Wnt Pathway Is Implicated in Exercise-Induced Improvement of Short-term Memory in Cerebral Palsy Rats |
| Q91806990 | PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer |
| Q64377027 | [Mechanisms of recombinant adenovirus-mediated SD-HA fusion protein proliferation inhibition and induced apoptosis of K562 cells] |
| Q64274877 | mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy |
Search more.